Rise of GLP-1 drugs brings substantial litigation risk: DAC Beachcroft

Share!

Reinsurance News - Dec 18, 2025

Law firm DAC Beachcroft warns of surging product liability claims that come with the rise of popular Glucagon-like peptide-1 receptor agonists (or GLP-1s), drugs for obesity management. While drugs like Ozempic and Wegowy offer health benefits, their rapid adoption has sparked a wave of legal challe...

Read Full Article

Recommended Articles

Swiss Re flags accumulation risk in data centres as key underwriting challenge

Posted: Mar 27, 2026

The data centre industry is evolving into increasingly complex, high-energy-density facilities that...

XS Global appoints Daniel Abramson as Head of Construction Underwriting, APAC

Posted: Mar 27, 2026

XS Global, an independently owned managing general underwriting (MGU) platform, has announced the ap...

SEADRIF and AHA Centre sign agreement to advance disaster risk financing in Southeast Asia

Posted: Mar 27, 2026

The Southeast Asia Disaster Risk Insurance Facility (SEADRIF) Insurance Company, a regional initiati...